Susquehanna Fundamental Investments, LLC Glycomimetics Inc Transaction History

Susquehanna Fundamental Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.9 $49,981 - $81,788	-90,876 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $64,571 - $95,959	-44,841 Reduced 33.04%	90,876 $131,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $16,200 - $21,510	-9,000 Reduced 6.22%	135,717 $297,000
Q2 2021 Aug 11, 2021	BUY	$2.16 - $3.18 $227,702 - $335,229	105,418 Added 268.25%	144,717 $336,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $74,275 - $108,458	-25,701 Reduced 39.54%	39,299 $118,000
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $77,741 - $122,536	-28,900 Reduced 30.78%	65,000 $244,000
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $255,731 - $416,500	83,300 Added 785.85%	93,900 $288,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $21,836 - $39,856	10,600 New	10,600 $40,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.